Drug · CHEMBL367149
DOCONEXENT
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DOCONEXENT. Drugs and targets, record CHEMBL367149. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL367149
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 22:6 n-3, C22:6 (n-3), Cervonic acid, Doconexento, Docosaheaenoic-acid, Docosahexaenoate, Docosahexaenoic acid, Docosahexaenoic acid (c22:6 n3), Docosahexanoic acid
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases45
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 45Source Open Targets
See all 45 diseasesTrials68
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 35 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00345176 | Age-Related Eye Disease Study 2 (AREDS2) | Phase 3 | 4,203 | 2013-12-24 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT00440050 | DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease | Phase 3 | 402 | 2010-08-30 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT01576783 | Omega Tots: A Randomized, Controlled Trial of Long-chain Polyunsaturated Fatty Acid Supplementation of Toddler Diets and Developmental Outcomes | Phase 4 | 377 | 2019-05-24 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT00266825 | DHA Supplementation and Pregnancy Outcome | Phase 3 | 350 | 2016-02-04 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT04198805 | Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) | Phase 2 | 205 | 2023-05-25 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT02487771 | Kansas University DHA Outcome Study (KUDOS) Follow-Up | Phase 3 | 190 | 2017-09-25 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT01027143 | Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids | Phase 2/3 | 143 | 2023-09-08 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT01661764 | Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention | Phase 2 | 141 | 2018-05-08 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT00711971 | Does Fish Oil Prevent Depression in Pregnancy and Postpartum? | Phase 2/3 | 126 | 2017-04-28 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
| NCT01078909 | Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation | Phase 3 | 125 | 2017-06-14 | docosahexaenoic acid | Its name | ClinicalTrials.gov |
1 to 10 of 68
See all 68 trialsComparisons in its trials41
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Docosahexaenoic Acid (DHA) vs Placebo: serious adverse events | 76 of 238 | 50 of 164 | 402 | NCT00440050 | Trial comparisons |
| Docosahexaenoic Acid + Arachidonic Acid vs Placebo: deaths from any cause | 0 of 189 | 0 of 188 | 377 | NCT01576783 | Trial comparisons |
| Docosahexaenoic Acid + Arachidonic Acid vs Placebo: serious adverse events | 0 of 189 | 0 of 188 | 377 | NCT01576783 | Trial comparisons |
| Docosahexaenoic Acid + Arachidonic Acid vs Placebo: Other Long-term Outcomes: Number of Participants With Behavior Difficulties | 5 of 133 | 1 of 116 | 249 | NCT01576783 | Trial comparisons |
| Docosahexaenoic Acid + Arachidonic Acid vs Placebo: Other Long-term Outcomes: Number of Participants With Developmental Delay | 30 of 133 | 18 of 116 | 249 | NCT01576783 | Trial comparisons |
| Omega-3 Fatty Acids vs Control: deaths from any cause | 0 of 77 | 0 of 21 | 98 | NCT01027143 | Trial comparisons |
| Omega-3 Fatty Acids vs Control: serious adverse events | 3 of 77 | 0 of 21 | 98 | NCT01027143 | Trial comparisons |
| Enteral Fish Oil vs Enteral Saline: serious adverse events | 12 of 41 | 10 of 49 | 90 | NCT00351533 | Trial comparisons |
| Enteral Fish Oil vs Enteral Saline: Hospital Mortality | 9 of 41 | 10 of 48 | 89 | NCT00351533 | Trial comparisons |
| Enteral Fish Oil vs Enteral Saline: 60-day Mortality | 9 of 41 | 11 of 45 | 86 | NCT00351533 | Trial comparisons |
1 to 10 of 41
See all 41 comparisons in its trialsPapers from its trials105
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials5
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Fluency | 2 | 1 | ConductCognition |
| Dimensional Change Card Sort | 1 | 1 | ConductCognition |
| Digit Span Test | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
| Vocabulary Test | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL367149
GET https://conductscience.org/api/drugs/v1/CHEMBL367149/diseases?page=2